Notably, we also observed a substantial elevation in the expression of FDXR within tumor cells subjected to the combined treatment (Figure 5E), thereby providing additional experimental support for the hypothesis that p53 enhances elesclomol-Cu-induced cuproptosis by upregulating the expression of FDXR. Here, TP53 is linked to neoplasm.